Top Markets
Coin of the day
GenSight Biologics S.A. GenSight Biologics S.A.

GenSight Biologics S.A.

SIGHT
Pozycja w akcjach #29609
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on... GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Cena akcji
$0.12715583
Kapitalizacja rynkowa
$20.73M
Zmiana (1 dzień)
2.49%
Zmiana (1 rok)
-36.91%
Kraj
FR
Handel GenSight Biologics S.A. (SIGHT)

Kategoria

Historia ceny akcji dla GenSight Biologics S.A. (SIGHT)
Najwyższa cena zamknięcia: $0.11 dnia 2026-08-01

Najniższa cena zamknięcia: $8.93 dnia 2016-07-01
Historia cen akcji firmy GenSight Biologics S.A. od 2016 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) 0.84%
2025 -61.96%
2024 -40.41%
2023 -85.79%
2022 -40.62%
2021 -23.84%
2020 252.34%
2019 -43.91%
2018 -36.71%
2017 -20.44%
2016 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$527.89 35.09%
US
$996.61 51.72%
NL
$117.42 -19.34%
AU
$749.90 8.10%
CH
$1.07K -5.58%
KR